Detecting adaptive immunity: Applications in transplantation monitoring

Molecular Diagnosis and Therapy

Volumn 14, Issue 1, 2010, Pages 1-11

  Böhmig, Georg A ^a   Wahrmann, Markus ^a   Säemann, Marcus D ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALLOANTIBODY; CD30 ANTIGEN; COMPLEMENT COMPONENT C4D; GAMMA INTERFERON; HLA ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 5; MESSENGER RNA; RAPAMYCIN; T LYMPHOCYTE RECEPTOR;

ADAPTIVE IMMUNITY; ALLOIMMUNITY; ANTIBODY DETECTION; ANTIBODY PRODUCTION; B LYMPHOCYTE; CLINICAL ASSESSMENT; CYTOKINE RELEASE; DISEASE MARKER; DRUG EFFECT; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GRAFT RECIPIENT; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; KIDNEY TRANSPLANTATION; MASS SPECTROMETRY; MICROARRAY ANALYSIS; MIXED LYMPHOCYTE REACTION; NOTE; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; T LYMPHOCYTE ACTIVATION; URINALYSIS;

ADAPTIVE IMMUNITY; ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; RISK ASSESSMENT; TRANSPLANTATION TOLERANCE;

EID: 76949099603     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/BF03256348     Document Type: Note

References (112)

1. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55 (2): 713-723 (Pubitemid 29082898)
2. Racusen LC, Halloran PF, Solez K. Banff 2003 meeting report: new diagnostic insights and standards. Am J Transplant 2004; 4 (10): 1562-1566
3. SolezK, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions.AmJ Transplant 2008; 8 (4): 753-760
4. Kozakowski N, Regele H. Biopsy diagnostics in renal allograft rejection: from histomorphology to biological function. Transpl Int 2009; 22 (10): 945-953
5. Böhmig GA, Regele H, Hörl WH. Protocol biopsies after kidney transplantation. Transpl Int 2005; 18 (2): 131-139
6. ThaunatO,LegendreC,Morelon E, et al.To biopsy or not to biopsy? Shouldwe screen the histology of stable renal grafts? Transplantation 2007; 84 (6): 671-676
7. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant 2006; 6 (9): 2006-2012
8. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6 (4): 747-752
9. Rush D. Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin J Am Soc Nephrol 2006; 1 (1): 138-143
10. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007; 7 (11): 2538-2545
11. Furness PN, Philpott CM, Chorbadjian MT, et al. Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation 2003; 76 (6): 969-973
12. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280 (14): 735-739
13. McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation 2000; 69 (3): 319-326
14. Gebel HM, Bray RA, Nickerson P. Pre-transplant assessment of donorreactive, HLA-specific antibodies in renal transplantation: contraindication vs risk. Am J Transplant 2003; 3 (12): 1488-1500
15. Terasaki PI.Humoral theory of transplantation. Am J Transplant 2003; 3 (6): 665-673
16. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3 (6): 708-714
17. Flechner SM, Kerman RH, Van Buren CT, et al. The use of cyclosporine in living-related renal transplantation: donor-specific hyporesponsiveness and steroid withdrawal. Transplantation 1984; 38 (6): 685-691
18. Reinsmoen NL, Matas AJ. Evidence that improved late renal transplant outcome correlates with the development of in vitro donor antigen-specific hyporeactivity. Transplantation 1993; 55 (5): 1017-1023
19. Ghobrial II, Morris AG, Booth LJ. Clinical significance of in vitro donorspecific hyporesponsiveness in renal allograft recipients as demonstrated by the MLR. Transpl Int 1994; 7 (6): 420-427
20. Böhmig GA, Säemann MD, Bergmann M, et al. Long-term evaluation of proliferative donor antigen-specific reactivity in cadaveric kidney transplant recipients. Transpl Int 2000; 13 (3): 187-193
21. Stiller CR, Sinclair NR, Abrahams S, et al. Transplant monitoring: patterns of the immune response. Proc Eur Dial Transplant Assoc 1976; 12: 415-422
22. Kristensen T, Grunnet N, Hansen HE, et al. Immunological diagnosis of rejection in human renal allotransplanted patients: a prospective study. Proc Eur Dial Transplant Assoc 1977; 14: 313-320
23. Goulmy E, Persijn G, Blokland E, et al. Cell-mediated lympholysis studies in renal allograft recipients. Transplantation 1981; 31 (3): 210-217
24. Carrodeguas L, Orosz CG, Waldman WJ, et al. Trans vivo analysis of human delayed-type hypersensitivity reactivity. Hum Immunol 1999; 60 (8): 640-651
25. VanBuskirk AM, Burlingham WJ, Jankowska-Gan E, et al. Human allograft acceptance is associated with immune regulation. J Clin Invest 2000; 106 (1): 145-155
26. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358 (4): 353-361
27. van Besouw NM, van der Mast BJ, de Kuiper P, et al. Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced. Transplantation 2000; 70 (1): 136-143
28. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17 (2): 77-88
29. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006; 82 (5): 663-668
30. Zeevi A, Britz JA, Bentlejewski CA, et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 2005; 15 (1): 17-24
31. Serban G, Whittaker V, Fan J, et al. Significance of immune cell function monitoring in renal transplantation after Thymoglobulin induction therapy. Hum Immunol 2009 Nov; 70 (11): 882-890
32. Gebauer BS, Hricik DE, Atallah A, et al. Evolution of the enzyme-linked immunosorbent spot assay for post-transplant alloreactivity as a potentially useful immune monitoring tool. Am J Transplant 2002; 2 (9): 857-866
33. Hricik DE, Rodriguez V, Riley J, et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003; 3 (7): 878-884
34. Nickel P, Presber F, Bold G, et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12 months in renaltransplant recipients. Transplantation 2004; 78 (11): 1640-1646
35. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19 (7): 1419-1429
36. Tary-Lehmann M, Hricik DE, Justice AC, et al. Enzyme-linked immunosorbent assay spot detection of interferon-gamma and interleukin 5-producing cells as a predictive marker for renal allograft failure. Transplantation 1998; 66 (2): 219-224
37. van den Boogaardt DE, van Miert PP, de Vaal YJ, et al. The ratio of interferon- gamma and interleukin-10 producing donor-specific cells as an in vitro monitoring tool for renal transplant patients. Transplantation 2006; 82 (6): 844-848
38. Macedo C, Orkis EA, Popescu I, et al. Contribution of naive and memory Tcell populations to the human alloimmune response. Am J Transplant 2009; 9 (9): 2057-2066
39. Süsal C, Opelz G. Options for immunologic support of renal transplantation through the HLA and immunology laboratories. Am J Transplant 2007; 7 (6): 1450-1456
40. Zachary AA, Leffell MS. Detecting and monitoring human leukocyte antigen- specific antibodies. Hum Immunol 2008; 69 (10): 591-604
41. Tait BD, Hudson F, Cantwell L, et al. Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009; 14 (2): 247-254
42. Solez K, Colvin RB, Racusen LC, et al. Banff '05 meeting report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant 2007; 7 (3): 518-526
43. Böhmig GA, Exner M, Habicht A, et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002; 13 (4): 1091-1099
44. Mauiyyedi S, CrespoM, Collins AB, et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13 (3): 779-787
45. Terasaki PI, Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial. Transplantation 2005; 80 (9): 1194-1197
46. Bartel G, Regele H, Wahrmann M, et al. Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes. Am J Transplant 2008; 8 (12): 2652-2660
47. LachmannN, Terasaki PI, BuddeK, et al. Anti-human leukocyte antigen and donor-specific antibodies detected by Luminex posttransplant serve as biomarkers for chronic rejection of renal allografts. Transplantation 2009; 87 (10): 1505-1513
48. Böhmig GA, Bartel G, Regele H, et al. Prospects and limitations of posttransplantation alloantibody detection in renal transplantation. Hum Immunol 2009 Aug; 70 (8): 640-644
49. Suberbielle C, Legendre C, ChkoffN, et al. Anti-HLA sensitization after renal transplant excision: a retrospective study in 84 patients. Transplant Proc 1996; 28 (5): 2814
50. Adeyi OA, Girnita AL, Howe J, et al. Serum analysis after transplant nephrectomy reveals restricted antibody specificity patterns against structurally defined HLA class I mismatches. Transpl Immunol 2005; 14 (1): 53-62
51. Billen EV, Christiaans MH, Lee J, et al. Donor-directed HLA antibodies before and after transplantectomy detected by the Luminex single antigen assay. Transplantation 2009; 87 (4): 563-569
52. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of alloantibodysecreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8 (1): 133-143
53. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9 (1): 201-209
54. Han M, Rogers JA, Lavingia B, et al. Peripheral blood B cells producing donor-specific HLA antibodies in vitro. Hum Immunol 2009; 70 (1): 29-34
55. Fan X, Ang A, Pollock-Barziv SM, et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. NatMed 2004; 10 (11): 1227-1233
56. Pelzl S, Opelz G, Wiesel M, et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 2002; 73 (1): 3-6
57. Süsal C, Pelzl S, Döhler B, et al. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 2002; 13 (6): 1650-1656
58. Süsal C, Pelzl S, Opelz G. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30. Transplantation 2003; 76 (8): 1231-1232
59. Rajakariar R, Jivanji N, Varagunam M, et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 2005; 5 (8): 1922-1925
60. Platt RE, Wu KS, Poole K, et al. Soluble CD30 as a prognostic factor for outcome following renal transplantation. J Clin Pathol 2009; 62 (7): 662-663
61. Slavcev A, Honsova E, Lodererova A, et al. Soluble CD30 in patients with antibody-mediated rejection of the kidney allograft. Transpl Immunol 2007; 18 (1): 22-27
62. Pelzl S, Opelz G, Daniel V, et al. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 2003; 75 (3): 421-423
63. Langan LL, Park LP, Hughes TL, et al. Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival. Am J Transplant 2007; 7 (4): 847-856
64. Weimer R, Süsal C, Yildiz S, et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 2006; 6 (8): 1865-1874
65. Nafar M, Farrokhi F, Vaezi M, et al. Pre-transplant and post-transplant soluble CD30 for prediction and diagnosis of acute kidney allograft rejection. Int Urol Nephrol 2009; 41 (3): 687-693
66. Cervelli C, Fontecchio G, Scimitarra M, et al. Evaluation of serum sCD30 in renal transplantation patients with and without acute rejection. Transplant Proc 2009; 41 (4): 1159-1161
67. Sebille F, Gagne K, Guillet M, et al. Direct recognition of foreign MHC determinants by naive T cells mobilizes specific Vbeta families without skewing of the complementarity-determining region 3 length distribution. J Immunol 2001; 167 (6): 3082-3088
68. GagneK, Brouard S, GiralM, et al. Highly altered V beta repertoire of T cells infiltrating long-term rejected kidney allografts. J Immunol 2000; 164 (3): 1553-1563
69. Brouard S, Dupont A, Giral M, et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am J Transplant 2005; 5 (2): 330-340
70. Boros P, Bromberg JS. Human FOXP3+ regulatory T cells in transplantation. Am J Transplant 2009; 9 (8): 1719-1724
71. Suciu-Foca N, Manavalan JS, Scotto L, et al. Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review. Int Immunopharmacol 2005; 5 (1): 7-11
72. Chang CC, Ciubotariu R, Manavalan JS, et al. Tolerization of dendritic cells by T(S) cells: the crucial role of inhibitory receptors ILT3 and ILT4. Nat Immunol 2002; 3 (3): 237-243
73. Pretagostini R, Cinti P, Lai Q, et al. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival. Transpl Immunol 2008; 20 (1-2): 3-5
74. Dijke IE, Korevaar SS, Caliskan K, et al. Inadequate immune regulatory function ofCD4+CD25bright+FoxP3+ T cells in heart transplant patientswho experience acute cellular rejection. Transplantation 2009; 87 (8): 1191-1200
75. Yapici U, Bemelman FJ, Scheepstra CG, et al. Intragraft FOXP3 protein or mRNA during acute renal allograft rejection correlates with inflammation, fibrosis, and poor renal outcome. Transplantation 2009; 87 (9): 1377-1380
76. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007; 84 (8): 956-964
77. Dijke IE, Weimar W, Baan CC. Regulatory T cells after organ transplantation: where does their action take place? Hum Immunol 2008; 69 (7): 389-398
78. Kreijveld E, Koenen HJ, van Cranenbroek B, et al. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS One 2008; 3 (7): e2711
79. Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009; 20 (5): 1149-1160
80. Mengel M, Reeve J, Bunnag S, et al. Molecular correlates of scarring in kidney transplants: the emergence of mast cell transcripts. Am J Transplant 2009; 9 (1): 169-178
81. Perco P, Kainz A, Wilflingseder J, et al. Histogenomics: association of gene expression patterns with histological parameters in kidney biopsies. Transplantation 2009; 87 (2): 290-295
82. Saint-Mezard P, Berthier CC, Zhang H, et al. Analysis of independent microarray datasets of renal biopsies identifies a robust transcript signature of acute allograft rejection. Transpl Int 2009; 22 (3): 293-302
83. Flechner SM, Kurian SM, Head SR, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4 (9): 1475-1489
84. Deng MC, Eisen HJ, Mehra MR, et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6 (1): 150-160
85. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci U S A 2007; 104 (39): 15448-15453
86. Braud C, Baeten D, Giral M, et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. J Cell Biochem 2008; 103 (6): 1681-1692
87. Murphy GP, Williams PD, Merrin CE. Diagnostic value of lymphocyturia in renal allograft rejection in man. Urology 1973; 2 (3): 227-230
88. Grunewald RW, Fiedler GM, Stock B, et al. Immunocytological determination of lymphocytes and monocytes/macrophages in urinary sediments of renal allograft recipients. Nephrol Dial Transplant 2000; 15 (6): 888-892
89. Margreiter R, Fuchs D, Hausen A, et al. Neopterin as a new biochemical marker for diagnosis of allograft rejection: experience based upon evaluation of 100 consecutive cases. Transplantation 1983; 36 (6): 650-653
90. Reibnegger G, Aichberger C, Fuchs D, et al. Posttransplant neopterin excretion in renal allograft recipients: a reliable diagnostic aid for acute rejection and a predictive marker of long-term graft survival. Transplantation 1991; 52 (1): 58-63
91. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messengerRNAfor perforin and granzyme B in urine. N Engl J Med 2001; 344 (13): 947-954
92. Kotsch K, Mashreghi MF, Bold G, et al. Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejection. Transplantation 2004; 77 (12): 1866-1875
93. Dadhania D, Muthukumar T, Ding R, et al. Molecular signatures of urinary cells distinguish acute rejection of renal allografts from urinary tract infection. Transplantation 2003; 75 (10): 1752-1754
94. Ozbay A, Torring C, Olsen R, et al. Transcriptional profiles in urine during acute rejection, bacteriuria, CMV infection and stable graft function after renal transplantation. Scand J Immunol 2009; 69 (4): 357-365
95. Yannaraki M, Rebibou JM, Ducloux D, et al. Urinary cytotoxic molecular markers for a noninvasive diagnosis in acute renal transplant rejection. Transpl Int 2006; 19 (9): 759-768
96. Ding R, Li B,Muthukumar T, et al.CD103mRNAlevels in urinary cells predict acute rejection of renal allografts. Transplantation 2003; 75 (8): 1307-1312
97. Tatapudi RR, Muthukumar T, Dadhania D, et al. Noninvasive detection of renal allograft inflammation by measurements of mRNA for IP-10 and CXCR3 in urine. Kidney Int 2004; 65 (6): 2390-2397
98. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353 (22): 2342-2351
99. Renesto PG, Ponciano VC, Cenedeze MA, et al. High expression of Tim-3 mRNA in urinary cells from kidney transplant recipients with acute rejection. Am J Transplant 2007; 7 (6): 1661-1665
100. Manfro RC, Aquino-Dias EC, Joelsons G, et al. Noninvasive Tim-3 messenger RNA evaluation in renal transplant recipients with graft dysfunction. Transplantation 2008; 86 (12): 1869-1874
101. Schaub S, Rush D, Wilkins J, et al. Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J Am Soc Nephrol 2004; 15 (1): 219-227
102. Schaub S, Wilkins JA, Antonovici M, et al. Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am J Transplant 2005; 5 (4 Pt 1): 729-738
103. Schaub S, Mayr M, Hönger G, et al. Detection of subclinical tubular injury after renal transplantation: comparison of urine protein analysis with allograft histopathology. Transplantation 2007; 84 (1): 104-112
104. O'Riordan E, Orlova TN, Mei JJ, et al. Bioinformatic analysis of the urine proteome of acute allograft rejection. J Am Soc Nephrol 2004; 15 (12): 3240-3248
105. O'Riordan E, Orlova TN, Podust VN, et al. Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am J Transplant 2007; 7 (4): 930-940
106. MaoY,Yu J, Chen J, et al. Diagnosis of renal allograft subclinical rejection by urine protein fingerprint analysis. Transpl Immunol 2008; 18 (3): 255-259
107. Wang JN, Zhou Y, Zhu TY, et al. Prediction of acute cellular renal allograft rejection by urinary metabolomics using MALDI-FTMS. J Proteome Res 2008; 7 (8): 3597-3601
108. Zhang Y, Oetting WS, Harvey SB, et al. Urinary peptide patterns in native kidneys and kidney allografts. Transplantation 2009; 87 (12): 1807-1813
109. Quintana LF, Sole-Gonzalez A, Kalko SG, et al. Urine proteomics to detect biomarkers for chronic allograft dysfunction. J Am Soc Nephrol 2009; 20 (2): 428-435
110. Hu H, Kwun J, Aizenstein BD, et al. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation ofmultiple cytokines/ chemokines in urine. Transplantation 2009; 87 (12): 1814-1820
111. Bechtel U, Scheuer R, Landgraf R, et al. Assessment of soluble adhesion molecules (sICAM-1, sVCAM-1, sELAM-1) and complement cleavage products (sC4d, sC5b-9) in urine: clinical monitoring of renal allograft recipients. Transplantation 1994; 58 (8): 905-911
112. Hönger G, Mayr M, Dickenmann M, et al. Urinary C4d does not correlate with C4d-staining in peritubular capillaries but reflects nonspecific glomerular injury. Transplantation 2008; 85 (4): 542-546